Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6

doi:10.12998/wjcc.v3.i3.210

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8012)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

514

WORD

310

HTML

3716

Figures (1-2)

270

Tables (1-3)

341

Sum=5151

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1251

Download

1610

Sum=2861

Mar 16, 2015 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Cases. Mar 16, 2015; 3(3): 210-220
Published online Mar 16, 2015. doi: 10.12998/wjcc.v3.i3.210

Table 3 Studies reporting rates of sustained virological response to 48-wk interferon-based combination therapy in patients with hepatitis C genotype 5

Author/Country/Year	No. patients	Regimen	SVR
Legrand-Abravanel/France/2004[75]	12	Standard/Pegylated IFN plus RBV	63.60%
Delwaide/Belgium/2006[74]	6	Standard/Pegylated IFN plus RBV	83%
Bonny/France/2006[78]	87	Standard/Pegylated IFN plus RBV	60%
¹Antaki/Syria/2008[77]	26	Standard/Pegylated IFN plus RBV	54%
D’Heygere/Belgium/2011[79]	38	Standard/Pegylated IFN plus RBV	55.30%
Karatapanis/Greece/2012[29]	10	Pegylated IFN plus RBV	60%
Antaki/Syria/2012[76]	49	Standard/Pegylated IFN plus RBV	49%
Mauss/Germany/2012	24	Pegylated IFN plus RBV	58%
Papastergiou/Greece/2014[81]	27	Pegylated IFN plus RBV	63%

¹Thirteen out of 26 patients received 24 wk of treatment due to personal, financial or medical reasons. IFN: Interferon; RBV: Ribavirin; SVR: Sustained virological response.

Citation: Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3(3): 210-220
URL: https://www.wjgnet.com/2307-8960/full/v3/i3/210.htm
DOI: https://dx.doi.org/10.12998/wjcc.v3.i3.210